437 related articles for article (PubMed ID: 28361224)
21. [Immunotherapy of head and neck cancer. Current developments].
Schuler PJ; Hoffmann TK; Gauler TC; Bergmann C; Brandau S; Lang S
HNO; 2013 Jul; 61(7):559-72. PubMed ID: 23247754
[TBL] [Abstract][Full Text] [Related]
22. The safety of therapeutic monoclonal antibodies: implications for cancer therapy including immuno-checkpoint inhibitors.
Demlova R; Valík D; Obermannova R; ZdraŽilová-Dubská L
Physiol Res; 2016 Dec; 65(Suppl 4):S455-S462. PubMed ID: 28006927
[TBL] [Abstract][Full Text] [Related]
23. The paratumoral immune cell signature reveals the potential for the implementation of immunotherapy in esophageal carcinoma patients.
Strizova Z; Snajdauf M; Stakheev D; Taborska P; Vachtenheim J; Biskup J; Lischke R; Bartunkova J; Smrz D
J Cancer Res Clin Oncol; 2020 Aug; 146(8):1979-1992. PubMed ID: 32447483
[TBL] [Abstract][Full Text] [Related]
24. [Immunomodulation as innovative therapy for head and neck tumors : Current developments].
Schuler PJ; Doescher JC; Laban S; Hoffmann TK
HNO; 2016 Jul; 64(7):470-8. PubMed ID: 26912050
[TBL] [Abstract][Full Text] [Related]
25. Advances in the pharmacotherapeutic management of esophageal squamous cell carcinoma.
Peng C; Cohen DJ
Expert Opin Pharmacother; 2021 Jan; 22(1):93-107. PubMed ID: 33034212
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of lymphocyte infiltration following preoperative chemoradiotherapy and hyperthermia for esophageal cancer.
Morita M; Kuwano H; Araki K; Egashira A; Kawaguchi H; Saeki H; Kitamura K; Ohno S; Sugimachi K
Int J Radiat Oncol Biol Phys; 2001 Apr; 49(5):1259-66. PubMed ID: 11286832
[TBL] [Abstract][Full Text] [Related]
27. Pembrolizumab as a first-line therapy in spinocellular esophageal cancer.
Křížová L; Charvát F; Petruželka L
Klin Onkol; 2021; 34(1):59-61. PubMed ID: 33657821
[TBL] [Abstract][Full Text] [Related]
28. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
29. Promising immunotherapies for esophageal cancer.
Tanaka T; Nakamura J; Noshiro H
Expert Opin Biol Ther; 2017 Jun; 17(6):723-733. PubMed ID: 28366014
[TBL] [Abstract][Full Text] [Related]
30. Introduction: Cancer Immunology Special Issue-Immunotherapy.
Kawakami Y
Int Immunol; 2016 Jul; 28(7):317. PubMed ID: 27313100
[No Abstract] [Full Text] [Related]
31. New Approaches for Immune Directed Treatment for Ovarian Cancer.
Hardwick N; Frankel PH; Cristea M
Curr Treat Options Oncol; 2016 Mar; 17(3):14. PubMed ID: 26942589
[TBL] [Abstract][Full Text] [Related]
32. The next generation of immunotherapy: keeping lung cancer in check.
Somasundaram A; Burns TF
J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399
[TBL] [Abstract][Full Text] [Related]
33. The accumulation and prognosis value of tumor infiltrating IL-17 producing cells in esophageal squamous cell carcinoma.
Lv L; Pan K; Li XD; She KL; Zhao JJ; Wang W; Chen JG; Chen YB; Yun JP; Xia JC
PLoS One; 2011 Mar; 6(3):e18219. PubMed ID: 21483813
[TBL] [Abstract][Full Text] [Related]
34. Anti-PD-1 monoclonal antibody-resistant esophageal squamous cell carcinoma showing the abscopal effect: A case report with T-cell receptor/B-cell receptor repertoire analysis.
Takehara Y; Mimura K; Suzuki Y; Watanabe Y; Yoshimoto Y; Saze Z; Sato H; Tamaki T; Kono K
Cancer Rep (Hoboken); 2023 Jul; 6(7):e1832. PubMed ID: 37165926
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease.
Yu SS; Dorff TB; Ballas LK; Sadeghi S; Skinner EC; Quinn DI
Clin Adv Hematol Oncol; 2017 Jun; 15(6):466-477. PubMed ID: 28749907
[TBL] [Abstract][Full Text] [Related]
36. [Combined preoperative radiochemotherapy in squamous cell carcinoma. The view of the medical oncologist].
Stahl M
Chirurg; 2009 Nov; 80(11):1006-10. PubMed ID: 19730797
[TBL] [Abstract][Full Text] [Related]
37. Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.
Prat A; Navarro A; Paré L; Reguart N; Galván P; Pascual T; Martínez A; Nuciforo P; Comerma L; Alos L; Pardo N; Cedrés S; Fan C; Parker JS; Gaba L; Victoria I; Viñolas N; Vivancos A; Arance A; Felip E
Cancer Res; 2017 Jul; 77(13):3540-3550. PubMed ID: 28487385
[TBL] [Abstract][Full Text] [Related]
38. Local immune response to tumor invasion in esophageal squamous cell carcinoma. The expression of human leukocyte antigen-DR and lymphocyte infiltration.
Sadanaga N; Kuwano H; Watanabe M; Maekawa S; Mori M; Sugimachi K
Cancer; 1994 Jul; 74(2):586-91. PubMed ID: 8033037
[TBL] [Abstract][Full Text] [Related]
39. Human Tumor Antigens and Cancer Immunotherapy.
Vigneron N
Biomed Res Int; 2015; 2015():948501. PubMed ID: 26161423
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma.
Jiang Y; Lo AWI; Wong A; Chen W; Wang Y; Lin L; Xu J
Oncotarget; 2017 May; 8(18):30175-30189. PubMed ID: 28404915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
